Gilead Sciences, Inc. (GILD) Receives New Coverage from Analysts at CIBC

CIBC initiated coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report issued on Thursday morning. The firm issued a market perform rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on GILD. BidaskClub cut Gilead Sciences from a buy rating to a hold rating in a research report on Wednesday, August 9th. Mizuho reiterated a buy rating on shares of Gilead Sciences in a research report on Friday, September 29th. Deutsche Bank AG reiterated a buy rating and set a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Jefferies Group LLC started coverage on Gilead Sciences in a research report on Thursday. They set a positive rating on the stock. Finally, Bank of America Corporation lowered their price objective on Gilead Sciences from $87.00 to $86.00 and set a neutral rating on the stock in a research report on Wednesday, October 4th. Twelve investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $85.66.

Shares of Gilead Sciences (GILD) opened at 82.14 on Thursday. The firm’s 50-day moving average is $80.97 and its 200-day moving average is $71.66. The firm has a market cap of $107.27 billion, a P/E ratio of 8.92 and a beta of 1.14. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the prior year, the business earned $3.08 EPS. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences will post $8.75 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/09/gilead-sciences-inc-gild-receives-new-coverage-from-analysts-at-cibc.html.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio is 22.58%.

In other news, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the sale, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 486,819 shares of company stock valued at $39,298,919. Corporate insiders own 1.30% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Fulton Bank N.A. boosted its position in shares of Gilead Sciences by 5.0% during the third quarter. Fulton Bank N.A. now owns 50,157 shares of the biopharmaceutical company’s stock valued at $4,064,000 after buying an additional 2,391 shares during the last quarter. Curbstone Financial Management Corp boosted its position in shares of Gilead Sciences by 101.6% during the third quarter. Curbstone Financial Management Corp now owns 28,170 shares of the biopharmaceutical company’s stock valued at $2,282,000 after buying an additional 14,200 shares during the last quarter. Perpetual Ltd boosted its position in shares of Gilead Sciences by 10.1% during the second quarter. Perpetual Ltd now owns 175,900 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 16,100 shares during the last quarter. Intl Fcstone Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,110,000. Finally, Griffin Asset Management Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,151,000. 73.98% of the stock is currently owned by in

Several other research firms have also recently weighed in on GILD. BidaskClub cut Gilead Sciences from a buy rating to a hold rating in a research report on Wednesday, August 9th. Mizuho reiterated a buy rating on shares of Gilead Sciences in a research report on Friday, September 29th. Deutsche Bank AG reiterated a buy rating and set a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Jefferies Group LLC started coverage on Gilead Sciences in a research report on Thursday. They set a positive rating on the stock. Finally, Bank of America Corporation lowered their price objective on Gilead Sciences from $87.00 to $86.00 and set a neutral rating on the stock in a research report on Wednesday, October 4th. Twelve investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $85.66.

Shares of Gilead Sciences (GILD) opened at 82.14 on Thursday. The firm’s 50-day moving average is $80.97 and its 200-day moving average is $71.66. The firm has a market cap of $107.27 billion, a P/E ratio of 8.92 and a beta of 1.14. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the prior year, the business earned $3.08 EPS. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences will post $8.75 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/09/gilead-sciences-inc-gild-receives-new-coverage-from-analysts-at-cibc.html.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio is 22.58%.

In other news, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the sale, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 486,819 shares of company stock valued at $39,298,919. Corporate insiders own 1.30% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Fulton Bank N.A. boosted its position in shares of Gilead Sciences by 5.0% during the third quarter. Fulton Bank N.A. now owns 50,157 shares of the biopharmaceutical company’s stock valued at $4,064,000 after buying an additional 2,391 shares during the last quarter. Curbstone Financial Management Corp boosted its position in shares of Gilead Sciences by 101.6% during the third quarter. Curbstone Financial Management Corp now owns 28,170 shares of the biopharmaceutical company’s stock valued at $2,282,000 after buying an additional 14,200 shares during the last quarter. Perpetual Ltd boosted its position in shares of Gilead Sciences by 10.1% during the second quarter. Perpetual Ltd now owns 175,900 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 16,100 shares during the last quarter. Intl Fcstone Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,110,000. Finally, Griffin Asset Management Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,151,000. 73.98% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply